Purpose: To evaluate the intraocular pressure (IOP) lowering effect and adverse event profile of the Implante Plano Miranda (IPM), a novel flat glaucoma drainage device. Methods: Prospective, single-arm, open-label Phase II clinical trial including 24 eyes with uncontrolled primary open-angle glaucoma (POAG) despite maximal tolerated medical therapy, undergoing standalone IPM implantation with adjunctive Mitomycin-C (MMC). Primary outcome was the proportion of eyes achieving surgical success, defined by: ≥ 20% IOP reduction from baseline on same or fewer medications without clinical hypotony or reoperation. Secondary outcomes included changes in IOP, medication burden, endothelial cell density (ECD), and adverse events. Patients were followed for 12 months. Results: At 12 months, surgical success was achieved in 79.5% of eyes. Median IOP decreased from 24.0 mmHg (IQR 24– 26) preoperatively to 14.0 mmHg (IQR 12– 17) at one year (p < 0.0001), representing a 41.6% reduction. Median glaucoma medications decreased from 4 (IQR 3– 4) to 1 (IQR 0– 3) (p < 0.0001). ECD remained stable (baseline 1,671.98 ± 570.75 vs. 12 months 1,684.37 ± 549.25 cells/mm 2 ; p = 0.797). Minor adverse events occurred in 29.1% of eyes; no serious complications or reoperations were reported. Conclusion: The IPM was associated with significant IOP reduction and decreased medication use at one year. No serious safety events were observed during the 12-month follow-up. Given the small sample size and single-arm design, larger controlled studies with longer follow-up are necessary to better define the safety and efficacy profile of this device. Keywords: flat glaucoma drainage device, implante plano miranda, glaucoma surgery, subconjunctival filtering
Francesco et al. (Wed,) studied this question.